All In Biotech

Drug Trial Radar · NCT02600598

Biological Effects of LEO 43204 in Actinic Keratosis

Biological Effects of LEO 43204 in Actinic Keratosis Assessed by Histopathology

Last checked: Nov 20, 2026Latest source record: Feb 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Jul 2016

Primary completion

Dec 27, 2016

Study completion Jan 16, 2017

Sponsor

Lead sponsor
LEO PharmaIndustry
Sponsor type
Industry
First posted
Nov 9, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase I, single-centre, open label, within-subject comparison trial to explore the biological effects of LEO 43204 Gel, 0.037%, applied once daily for 3 consecutive days in patients with actinic keratosis on the upper extremity. The treatment area for each patient will be as defined as a contiguous area of 250 cm2 of skin on the upper extremity (including the dorsum manus) that contains a minimum of 5 AK lesions. Additionally there must be at least one AK lesion located in a non-treated area on the contralateral arm. All eligible subjects will receive LEO 43204 Gel, 0.037%, on the treatment area on Days 1, 2 and 3. Study medication application will be (sub)investigator applied. A total of 30 patients will be enrolled into this study (n=15 in each of the two groups). Patients will be divided into two groups with different biopsy schedules.

Conditions

  • Actinic Keratosis

Interventions

  • LEO 43204 Gel, 0.037%Drug

  • LEO 43204 Gel, 0.037%Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of CD3+ T lymphocytes assessed by immunohistochemistry in biopsies from AK lesions 56 days after first treatment.Time frame: 56 days

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Beacon Clinical Research, LLC

    Quincy, Massachusetts

  • Long Island Skin Cancer and Dermatology Surgery

    Smithtown, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.